Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Wondering what typeface was used in any given video game? Charlotte Couderc's Game Font Library is exactly what it claims to be. You can search by game, genre, studio, typeface or even foundry. Game ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

Using the free designer on mobile, you can only change to preset colors and fonts - again, simple, but here, limited. Redesigning a logo in the browser allows for deeper customization. You have ...

As far as design aesthetics are concerned, the early logos were very straightforward. Each was “Super Bowl” followed by the appropriate Roman numerals. The font and colors changed each year ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive ... its colour palette (true blue and spark yellow), font ("everyday sans") and trademark "spark" symbol ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...